SOURCE: Radient Pharmaceuticals Corporation

Radient Pharmaceuticals Corporation

June 22, 2011 07:00 ET

Radient Pharmaceuticals to Exhibit at the National Conference for Colon Cancer Alliance

TUSTIN, CA--(Marketwire - Jun 22, 2011) - Radient Pharmaceuticals Corporation "RPC" or "the Company" (NYSE Amex: RPC), a developer and global marketer of In Vitro Diagnostic (IVD) cancer tests, today announced it will be an exhibitor at the Colon Cancer Alliance's National Conference in Denver, Colorado from June 23-25. The conference's theme, "Family Matters: What Every Family Needs to Know About Colon Cancer," is designed for families, survivors, caregivers, and all others affected by colon cancer.

The Colon Cancer Alliance (CCA) is the oldest and largest national patient advocacy organization dedicated to ending the suffering caused by colorectal cancer. In order to increase rates of screening and survivorship, the CCA provides patient support, public education, supports research, and conducts advocacy work across America.

The conference agenda will include national experts who will discuss topics specific to colon cancer including genetic risks, designing a treatment plan, advanced disease treatment options, and tips for living with colon cancer.

RPC's Onko-Sure® IVD is a simple, non-invasive blood test used both for monitoring colorectal cancer (CRC) during treatment and for post-treatment CRC recurrence monitoring. Onko-Sure® is cleared by the US FDA. Clinical studies show that Onko-Sure®, when used in combination with Carcinoembryonic Antigen (CEA), the current marker which is the standard of care, increases accuracy rates by up to 20%, particularly in Stage I and Stage II.

"Presenting Onko-Sure® to key stakeholders at the Colon Cancer Alliance's National Conference is very important to us. These CRC patients, their family members, and doctors are key decision makers looking for better solutions in the diagnosis and treatment of colorectal cancer. We are advocating for the use of Onko-Sure® in conjunction with CEA, which has been adopted as the standard of care, as the combination of these tests produces superior accuracy, leading to better patient outcomes," stated RPC's CEO Mr. Douglas MacLellan. "Furthermore, we will be engaged in a conference that is attended and sponsored by some of the leading names in global healthcare."

For more information on the Colon Cancer Alliance National Conference please visit:

The following chart is intended to provide the latest information on RPC's business metrics.

RPC's Business Metrics
Cash on hand: $1.7 million*
*Approximate amount as of June 20, 2011
Shares Outstanding: 124 million*
*Approximate number as of June 20, 2011 and there are 200 million shares fully authorized.
Outstanding Warrants & Options: 38.08 million*
*Approximate number as of June 20, 2011

For additional information on Radient Pharmaceuticals Corporation and its products please visit: or send an e-mail to For Investor Relations contact Kristine Szarkowitz at or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.